JAK Inhibitors for Pemphigoid Diseases

IF 3.4 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2025-09-22 DOI:10.1155/dth/6185003

Enkhbilguun Sodbuyan, Hyun Min Lee, Miklós Sárdy

{"title":"JAK Inhibitors for Pemphigoid Diseases","authors":"Enkhbilguun Sodbuyan, Hyun Min Lee, Miklós Sárdy","doi":"10.1155/dth/6185003","DOIUrl":null,"url":null,"abstract":"<p>Pemphigoid diseases are a group of chronic autoimmune blistering skin disorders, with bullous pemphigoid representing the most prevalent subtype. Bullous pemphigoid (BP) primarily affects individuals aged 60–80 years, and its incidence has been steadily rising in correlation with increasing life expectancy and population aging in Western countries. Autoantibodies targeting hemidesmosome proteins (collagen XVII and dystonin-e) at the dermal-epidermal junction activate complement recruiting inflammatory leukocytes that release proteolytic enzymes, degrading structural proteins and causing subepidermal blistering. The current standard treatments for pemphigoid diseases are corticosteroids and classical immunosuppressants. Systemic immunosuppression is not ideal in immunocompromised elderly patients, and more targeted and safer approaches, including dupilumab and omalizumab, are also being investigated. Our current priority is to explore further efficient and safe therapeutic options. Janus kinase (JAK) inhibitors have shown considerable potential as novel treatment options for chronic inflammatory and autoimmune diseases. The JAK inhibitors may offer efficient and safe treatment with rapid symptom improvement and disease control in the management of pemphigoid disorders. This review describes pemphigoid cases, including the rare forms, managed with JAK inhibitors (tofacitinib, baricitinib, upadacitinib, and abrocitinib).</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6185003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/6185003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pemphigoid diseases are a group of chronic autoimmune blistering skin disorders, with bullous pemphigoid representing the most prevalent subtype. Bullous pemphigoid (BP) primarily affects individuals aged 60–80 years, and its incidence has been steadily rising in correlation with increasing life expectancy and population aging in Western countries. Autoantibodies targeting hemidesmosome proteins (collagen XVII and dystonin-e) at the dermal-epidermal junction activate complement recruiting inflammatory leukocytes that release proteolytic enzymes, degrading structural proteins and causing subepidermal blistering. The current standard treatments for pemphigoid diseases are corticosteroids and classical immunosuppressants. Systemic immunosuppression is not ideal in immunocompromised elderly patients, and more targeted and safer approaches, including dupilumab and omalizumab, are also being investigated. Our current priority is to explore further efficient and safe therapeutic options. Janus kinase (JAK) inhibitors have shown considerable potential as novel treatment options for chronic inflammatory and autoimmune diseases. The JAK inhibitors may offer efficient and safe treatment with rapid symptom improvement and disease control in the management of pemphigoid disorders. This review describes pemphigoid cases, including the rare forms, managed with JAK inhibitors (tofacitinib, baricitinib, upadacitinib, and abrocitinib).

查看原文本刊更多论文

JAK抑制剂治疗类天疱疮疾病

类天疱疮疾病是一组慢性自身免疫性皮肤病，与大疱性类天疱疮代表最普遍的亚型。大疱性类天疱疮（BP）主要影响60-80岁的人群，在西方国家，其发病率随着预期寿命的增加和人口老龄化而稳步上升。在真皮-表皮交界处靶向半脂酶蛋白（胶原XVII和dystonin-e）的自身抗体激活补体招募炎性白细胞，释放蛋白水解酶，降解结构蛋白并引起表皮下起泡。目前类天疱疮疾病的标准治疗方法是皮质类固醇和经典免疫抑制剂。对于免疫功能低下的老年患者，全身免疫抑制并不理想，更有针对性和更安全的方法，包括dupilumab和omalizumab，也正在研究中。我们目前的首要任务是探索进一步有效和安全的治疗选择。Janus激酶（JAK）抑制剂已显示出相当大的潜力，作为慢性炎症和自身免疫性疾病的新治疗选择。在类天疱疮疾病的治疗中，JAK抑制剂可以提供有效和安全的治疗方法，快速改善症状和控制疾病。这篇综述描述了类天疱疮病例，包括罕见的形式，用JAK抑制剂（托法替尼、巴西替尼、upadacitinib和阿布替尼）治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.